Industry warming to more user-friendly FDA inspections
This article was originally published in Clinica
Like paying taxes, FDA plant inspections have typically been something to endure - an unpleasant but necessary burden. But a new survey conducted by an FDA/industry committee under the auspices of the Medical Device Industry Initiatives Grassroots Task Force suggests companies are changing their minds about the FDA inspection process.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.